Fluorine 18 MNI 968

Drug Profile

Fluorine 18 MNI 968

Alternative Names: [18F]MNI 968; PF 06730110

Latest Information Update: 11 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Molecular NeuroImaging
  • Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neurodegenerative disorders

Most Recent Events

  • 01 May 2017 Phase-I clinical trials in Neurodegenerative disorders (Diagnosis, In volunteers) in USA (Parenteral) (NCT03142724)
  • 03 Mar 2017 Phase-0 for Neurodegenerative disorders (Diagnosis) in USA (Parenteral) (NCT03082768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top